# BPC-157 vs TB-500 - Canonical: https://residue.info/vs/bpc-157-vs-tb-500/ - Compounds: BPC-157 (https://residue.info/c/bpc-157/), TB-500 (https://residue.info/c/tb-500/) - Updated: 2026-10-19 · Reviewed by: Residue Editorial Team Both are research peptides linked to tissue repair; neither is FDA-approved [1]. BPC-157's evidence is mostly animal: 35 of 36 orthopedic studies in a 2025 systematic review were preclinical [2]. TB-500 is a seven-residue thymosin β4 fragment [3]; trials tested the full protein, mainly as eye drops [4], but FDA has identified no human exposure data for the fragment [1]. ## Side by side | | BPC-157 | TB-500 | |---|---|---| | What it is | Synthetic 15-residue peptide originally isolated from gastric juice [5] | Ac-LKKTETQ, thymosin β4 residues 17–23 [3] | | Proposed mechanism | VEGFR2 and Akt–eNOS signaling, angiogenesis [5] | Region linked to actin binding, cell migration, wound healing [6] | | Human data | Three small uncontrolled pilots [5] | None for the fragment; phase 2–3 for full thymosin β4 [4][7] | | Half-life | Under 30 minutes [2] | Not established in humans | | Registered studies | Phase 2 hamstring trial recruiting [8] | Phase 1/2 fragment study recruiting [9] | | FDA | Withdrawn nomination; insufficient safety information [1] | Withdrawn nomination; no human exposure data identified [1] | | Evidence grade | C | D | ## Where do they come from? BPC-157 ("body protection compound") is a synthetic 15-amino-acid peptide originally isolated from gastric juice [5]. TB-500 began as a veterinary preparation; its key ingredient is the seven-residue LKKTETQ segment of thymosin β4 with an N-terminal acetyl group [6], which mass spectrometry confirmed in a TB-500 product [3]. ## How are they thought to work? BPC-157 is not a defined receptor agonist. Reviews describe signaling through VEGFR2 and the Akt–eNOS (nitric oxide) pathway and promotion of angiogenesis, largely from animal and cell studies [5]. For TB-500, the rationale is that residues 17–23 are the active site within thymosin β4 for actin binding, cell migration and wound healing [6]. ## What does the human evidence show? **BPC-157.** A 2025 systematic review screened 544 articles and included 36 orthopedic studies: 35 preclinical and 1 clinical. It found no clinical safety data [2]. A narrative review counted three human pilot reports — knee pain, interstitial cystitis and an intravenous safety and pharmacokinetics study — none large or controlled [5]. **TB-500.** We found no human outcome study of the fragment; its human-relevant literature is anti-doping detection [3][6]. Full-length thymosin β4 has more: in a phase 2 dry-eye trial (72 subjects), neither primary endpoint was met, though several secondary endpoints improved [4], and eye-drop phase 3 programs followed [7]. Those results do not transfer automatically to a seven-residue fragment. ## Are they FDA-approved? Neither is FDA-approved. FDA lists BPC-157 and the LKKTETQ fragment among withdrawn compounding nominations; for the fragment it states it has not identified any human exposure data [1]. ## Can you take BPC-157 and TB-500 together? One retrospective phone survey reported 16 knee-pain patients who received intra-articular BPC-157 alone or with thymosin β4; 14 reported relief, without standardized outcome tools [10]. Neither peptide is FDA-approved for compounding [1]. ## Frequently asked questions **Is BPC-157 or TB-500 better for healing?** There is no comparative human evidence. BPC-157's orthopedic evidence is 35 preclinical studies and 1 clinical study [2]; the TB-500 fragment has no published human outcome study, and the trials that exist test full-length thymosin β4 [4]. **Have BPC-157 and TB-500 been studied together?** Only in a retrospective phone survey: 16 knee-pain patients received intra-articular BPC-157 alone or with thymosin β4, and 14 reported relief, without standardized outcome tools [10]. **Are they legal to compound?** Both appear on FDA's list of withdrawn compounding nominations, with FDA stating it lacks the safety information needed to know whether they would cause harm in humans [1]. **Can you take BPC-157 and TB-500 together?** One retrospective phone survey reported 16 knee-pain patients who received intra-articular BPC-157 alone or with thymosin β4; 14 reported relief, without standardized outcome tools [10]. Neither peptide is FDA-approved [1]. **What are the side effects of BPC-157 vs TB-500?** Published human safety data are sparse for both. A 2025 orthopedic review of BPC-157 found no clinical safety dataset [2]; FDA states it lacks human exposure data for the TB-500 fragment [1]. ## Sources [1] Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. FDA, content current as of 04/22/2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks [2] Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. Vasireddi N et al. HSS J. 2025. https://pubmed.ncbi.nlm.nih.gov/40756949/ [3] Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Esposito S et al. Drug Test Anal. 2012. https://pubmed.ncbi.nlm.nih.gov/22962027/ [4] Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model. Sosne G & Ousler GW Clin Ophthalmol. 2015. https://pubmed.ncbi.nlm.nih.gov/26056426/ [5] Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. McGuire FP et al. Curr Rev Musculoskelet Med. 2025. https://pubmed.ncbi.nlm.nih.gov/40789979/ [6] Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry. Ho EN et al. J Chromatogr A. 2012. https://pubmed.ncbi.nlm.nih.gov/23084823/ [7] Thymosin beta 4 and the eye: the journey from bench to bedside. Sosne G Expert Opin Biol Ther. 2018. https://pubmed.ncbi.nlm.nih.gov/30063853/ [8] BPC 157 for Acute Hamstring Muscle Strain Repair. Hudson Biotech · PHASE2 · recruiting. https://clinicaltrials.gov/study/NCT07437547 [9] TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD. Hudson Biotech · PHASE1/PHASE2 · recruiting. https://clinicaltrials.gov/study/NCT07487363 [10] Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Lee E & Padgett B Altern Ther Health Med. 2021. https://pubmed.ncbi.nlm.nih.gov/34324435/ --- From Residue. Research and education only; not medical advice. Quote with attribution and a link to the canonical page.